Safety and efficacy of desloratadine 5 mg in asthma patients with seasonal allergic rhinitis and nasal congestion

Annals of Allergy, Asthma and Immunology

Volumn 89, Issue 5, 2002, Pages 485-491

  Berger, William E ^a   Schenkel, Eric J ^b   Mansfield, Lyndon E ^c  

^a Southern California Research   (United States)

^b Valley Clinical Research Center   (United States)

^c El Paso Institute of Medical Research and Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; DESLORATADINE; PLACEBO;

ADOLESCENT; ADULT; AGED; ALLERGIC RHINITIS; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NOSE CONGESTION; PRIORITY JOURNAL; RHINORRHEA; SNEEZING; SYMPTOMATOLOGY; TREATMENT OUTCOME; TREATMENT PLANNING; XEROSTOMIA;

EID: 0036878326     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)62086-8     Document Type: Article

References (31)

1. American Academy of Allergy, Asthma, and Immunology. The Allergy Report, Volume 1: Overview of Allergic Diseases 2000. Milwaukee, WI: AAAAI, 2000.
2. Dykewicz MS, Fineman S, Skoner DP, et al. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 1998;81:478-518.
3. Schoenwetter WF. Allergic rhinitis: epidemiology and natural history. Allergy Asthma Proc 2000;21:1-6.
4. Sly RM. Changing prevalence of allergic rhinitis and asthma. Ann Allergy Asthma Immunol 1999;82:233-252.
5. Grossman J. One airway, one disease. Chest 1997;111:11S-16S.
6. Leynaert B, Neukirch F, Demoly P, et al. Epidemiologic evidence for asthma and rhinitis comorbidity. J Allergy Clin Immunol 2000;106(Suppl):S201-S205.
7. Simons FER. Allergic rhinobronchitis: the asthma-allergic rhinitis link. J Allergy Clin Immunol 1999;104:534-540.
8. DuBuske LM. The link between allergy and asthma. Allergy Asthma Proc 1999;20:341-345.
9. Welsh PW, Stricker WE, Chu CP, et al. Efficacy of beclomethasone nasal solution, flunisolide, and cromolyn in relieving symptoms of ragweed allergy. Mayo Clin Proc 1987;62:125-134.
10. Corren J. The relationship between allergic rhinitis and bronchial asthma. Curr Opin Pulm Med 1999;5:35-37.
11. Agrawal DK, Berro A, Townley RG. Desloratadine attenuation of eosinophil chemotaxis, adhesion, and superoxide generation. Allergy 2000;55(Suppl):276.
12. Agrawal DK. Pharmacology and clinical efficacy of desloratadine as an anti-allergic and anti-inflammatory drug. Exp Opin Invest Drugs 2001;10:547-560.
13. 1 receptor antagonist. 1st communication: receptor selectivity, antihistaminic activity, and antiallergenic effects. Arzneimittelforschung 2000;50:345-352.
14. 1-receptor antagonist, in patients with seasonal allergic rhinitis: assessment during the spring and fall allergy seasons. Clin Drug Invest 2001;21:25-32.
15. Horak F, Stübner UP, Zieglmayer R, et al. Onset and duration of action of desloratadine after controlled pollen challenges in patients with seasonal allergic rhinitis. Allergy 2000;55(Suppl):279.
16. 1-antagonist descarboethoxy-loratadine and dexamethasone by human mast and basophilic cell lines. Exp Dermatol 1995;4:272-276.
17. + cells. Clin Exp Allergy 1997;27:559-567.
18. Lichtenstein LM, Schroeder JT, Schleimer RP, et al. Inhibition of cytokine generation and mediator release in human basophils by desloratadine. J Allergy Clin Immunol 2001;107:S162.
19. Fridericia LS. Die Systolendauer im Elektrokardiogramm bei normalen Menschen and bei Herzranken. Acta Med Scand 1920;52:469-486.
20. Fireman P. Rhinitis and asthma connection: management of coexisting upper airway allergic diseases and asthma. Allergy Asthma Proc 2000;21:45-53.
21. Reed CE, Marcoux JP, Welsh PW. Effects of topical nasal treatment on asthma symptoms. J Allergy Clin Immunol 1988;81:1042-1047.
22. Nayak AS, Schenkel E. Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis. Allergy 2001;56:1077-1080.
23. Horak F, Stubner P, Zieglmayer R, et al. Desloratadine reduces nasal congestion and maintains nasal airflow in patients with seasonal allergic rhinitis exposed to allergen in the Vienna Challenge Chamber. Poster presentation at the 20th Congress of the European Academy of Allergology and Clinical Immunology, 9-13 May 2001, Berlin, Germany.
24. 1-receptor antagonists: safety issues. Ann Allergy Asthma Immunol 1999;83:481-488.
25. Marino M, Glue P, Herron JM, et al. Lack of electrocardiographic effects of multiple high doses of desloratadine. Allergy 2000;55(Suppl):279.
26. Affrime MB, Banfield C, Glue P, et al. Lack of electrocardiographic effects when desloratadine and ketoconazole are coadministered. Allergy 2000;55(Suppl):277.
27. Glue P, Banfield C, Affrime MB, et al. Lack of electrocardiographic interaction between desloratadine and erythromycin. Allergy 2000;55(Suppl):276.
28. Gupta S, Banfield C, Kantesaria B, et al. Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: a randomized, placebo-controlled, parallel-group study. Clin Ther 2001;23:451-466.
29. Cvetkovic M, Leake B, Fromm MF, et al. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 1999;27:866-871.
30. Dresser GK, Schwarz UI, Leake B, et al. Citrus juices are potent inhibitors of intestinal OATP but not P-glycoprotein. Clin Pharmacol Ther 2001;69:P23.
31. Silverman JA. In: Levy RH, editor. P-Glycoprotein. Philadelphia, PA: Lippincott Williams & Wilkins, 2000:135-144.